|8:00 a.m. -- 8:35 a.m.||Breakfast and registration|
|8:35 a.m. -- 9:45 a.m.||Presentations|
|9:45 a.m. -- 10:00 a.m.||Q&A|
|Convene, Bryant Park Hub|
|730 Third Avenue (between 45th and 46th Street)|
|New York, NY 10017|
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3, 2015, in New York City. At the breakfast, the Company will present the clinical development strategy for BL-8040, its lead oncology and hematology platform, for 2016 and beyond. The event will also include a keynote presentation by internationally-renowned key opinion leader, Dr. John DiPersio, Chief of the Division of Oncology at Washington University School of Medicine in St. Louis, entitled a "Review of the CXCR4 Landscape."
BioLineRx Ltd. will also host a live audio webcast of the investor breakfast. For access to the webcast, please go to the breakfast event page on BioLineRx's website. It is recommended that users register 15 minutes prior to the scheduled start time to ensure timely connection. An audio replay of the meeting will also be available for approximately three months following the meeting on the breakfast event page. Registration and Additional Information Advanced registration is required for onsite attendance. To register, please contact Vivian Cervantes at email@example.com. About BioLineRx BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.